Latest Freenome News & Updates

See the latest news and media coverage for Freenome. We track all announcements, press releases, and industry mentions in real time, all in one place.

Freenome

Biotech company developing blood tests for early cancer detection

freenome.com

Headquarters: Brisbane, United States
Founded year: 2014
Company type: Private company
Number of employees: 400–500
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Freenome

In short: Freenome went public on Nasdaq, received FDA approval for its colorectal cancer blood test, and obtained breakthrough status for lung cancer.

Company announcements

August 12 Freenome

Freenome receives FDA breakthrough designation for lung cancer testing

The AI-powered blood test targets high-risk adults to overcome existing screening barriers and accelerate regulatory review pathways.

August 4 Freenome

Freenome rings Nasdaq opening bell to celebrate its listing.

The company develops AI-powered blood-based screening tests to detect cancer at its earliest, treatable stages, aiming to make screening simple, accessible, and effective.

July 31 Freenome

Freenome celebrated FDA approval, IPO, and test results

The company's SimpleScreen CRC test received FDA approval, its stock began trading on Nasdaq, and an updated version showed improved detection of precancerous lesions.

July 27 Freenome

Freenome's SimpleScreen CRC receives FDA approval

Abbott will commercialize the test in the U.S., expanding colorectal cancer screening options for millions of overdue Americans.

Media coverage

August 28 RTTNews

Biotech Gainers: QNRX Leads Gains As AEMD, DWTX And FRNM Report Key Developments

Dogwood Therapeutics, Inc. (DWTX) shares gained 12% after the company reported second-quarter 2026 results and provided an update on its lead candidate Halneuron in a...

August 25 Ticker Report

Freenome (NASDAQ:FRNM) Given Average Recommendation of “Moderate Buy” by Brokerages - Ticker Report

Shares of Freenome (NASDAQ:FRNM – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering...

August 17 The Street

Jefferies sets strong price target on upstart cancer stock

Jefferies just initiated coverage on a small cancer-screening stock, and the target price points to...

August 14 Benzinga

Freenome Inc (FRNM) Stock Price, Quote, News & History

Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21 Guggenheim analyst Subbu Nambi initiates coverage on Freenome (NASDAQ:FRNM) with a Buy...

Never miss news about Freenome

Track Freenome and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Freenome competitors & trending companies

Browse news for competitors to Freenome and other trending companies.